As filed with the Securities and Exchange Commission on February 23, 2022

Registration No. 333-            

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

Coherus BioSciences, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   2836   27-3615821

(State or other jurisdiction of

incorporation or organization)

 

(Primary Standard Industrial

Classification Code Number)

 

(I.R.S. Employer

Identification Number)

333 Twin Dolphin Drive, Suite 600

Redwood City, CA 94065

(650) 649-3530

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

 

Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan

(Full Title of the Plan)

 

 

Dennis M. Lanfear

President and Chief Executive Officer

Coherus BioSciences, Inc.

333 Twin Dolphin Drive, Suite 600

Redwood City, CA 94065

(650) 649-3530

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

 

Copies to:

Benjamin A. Potter, Esq.

Phillip S. Stoup, Esq.

Latham & Watkins LLP

140 Scott Drive

Menlo Park, California 94025-1008

Telephone: (650) 328-4600

Facsimile: (650) 463-2600

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

 

 

 


REGISTRATION OF ADDITIONAL SECURITIES

Coherus BioSciences, Inc. (the “Company”) filed with the Securities and Exchange Commission a Registration Statement on Form S-8 (File No. 333-213077) on August 11, 2016 relating to shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), to be offered and sold under the Inducement Plan and the contents of the Registration Statements on Form S-8 filed with the securities and Exchange Commission on August 11, 2016 (File No. 333-213077), June 14, 2018 (File No. 333-225616), November 8, 2018 (File No. 333-228274), February 1, 2019 (File No. 333-229479), May 9, 2019 (File No. 333-231329), November 8, 2019 (File No. 333-234601), January 24, 2020 (File No. 333-236065) and January 4, 2021 (File No. 333-251877) are incorporated by reference in this Registration Statement. The Company is hereby registering an additional 1,000,000 shares of Common Stock issuable under the Inducement Plan, none of which have been issued as of the date of this Registration Statement.

Item 8. Exhibits.

Reference is made under this Item 8 to the exhibit index included in this Registration Statement.


INDEX TO EXHIBITS

 

        

Incorporated by Reference

        

Exhibit
Number

 

Description

  

Form

    

Exhibit

   

Date Filed

    

Filed
Herewith

 
    4.1   Amended and Restated Certificate of Incorporation of Coherus BioSciences, Inc.      8-K        3.1       11/13/2014     
    4.2   Amended and Restated Bylaws of Coherus BioSciences, Inc.      8-K        3.1       11/18/2020     
    4.3   Specimen Common Stock Certificate.      S-1/A        4.2       10/24/2014     
    5.1   Opinion of Latham & Watkins LLP.              X  
  23.1   Consent of Latham & Watkins LLP (included in Exhibit 5.1).              X  
  23.2   Consent of Independent Registered Public Accounting Firm.              X  
  24.1   Power of Attorney (included in the signature page to this registration statement).              X  
  99.1(a)#   Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan.      10-Q        10.1 (a)      8/9/2016     
  99.1(b)#   Form of Stock Option Grant Notice and Stock Option Agreement under the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan.      10-Q        10.1 (b)      8/9/2016     
  99.1(c)#   Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan.      10-Q        10.1 (c)      8/9/2016     
  99.1(d)#   Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan.      10-Q        10.1 (d)      8/9/2016     
107.1   Filing Fee Table              X  

 

#

Indicates management contract or compensatory plan.


SIGNATURES

Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Redwood City, California, on February 23, 2022.

 

COHERUS BIOSCIENCES, INC.
By:  

/s/ Dennis M. Lanfear

  Dennis M. Lanfear
  President and Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Dennis M. Lanfear and McDavid Stilwell, and each of them, with full power of substitution and full power to act without the other, his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file this Registration Statement, with all exhibits thereto, and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

 

Signature

  

Title

 

Date

/s/ Dennis M. Lanfear

Dennis M. Lanfear

   Chairman, President and Chief Executive Officer (Principal Executive Officer)   February 23, 2022

/s/ McDavid Stilwell

McDavid Stilwell

   Chief Financial Officer (Principal Financial and Accounting Officer)   February 23, 2022

/s/ Lee N. Newcomer

Lee N. Newcomer

   Director   February 23, 2022

/s/ Ali J. Satvat

Ali J. Satvat

   Director   February 23, 2022

/s/ Mark D. Stolper

Mark D. Stolper

   Director   February 23, 2022

/s/ Kimberly J. Tzoumakas

Kimberly J. Tzoumakas

   Director   February 23, 2022

/s/ Mats Wahlström

Mats Wahlström

   Director   February 23, 2022
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Coherus BioSciences Charts.
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Coherus BioSciences Charts.